Literature DB >> 27106907

The single intake of levodopa modulates implicit learning in drug naïve, de novo patients with idiopathic Parkinson's disease.

Sarah Geffe1, Katharina A Schindlbeck1, Arne Mehl1, Johann Jende2, Fabian Klostermann1, Frank Marzinzik3.   

Abstract

Although dopamine is known to aggravate implicit learning, the exact impact on behaviour when feedback is unavailable remains unclear. Previous studies revealed that non-rewarded learning habits are affected in long-term dopaminergic treated patients with Parkinson's disease (PD). We studied the influence of a onetime levodopa intake on implicit learning in de novo, untreated PD patients. De novo PD patients (n = 22) before and after the single intake of levodopa and control subjects (n = 23) took part in a Go/NoGo paradigm. One stimulus was defined as target, which was first consistently preceded by one of three non-target stimuli (conditioning). This coupling was dissolved thereafter (deconditioning). In the 'Go version' subjects were asked to respond to the target by pressing a key, whereas in the 'NoGo version' response had to be inhibited. PD patients and controls (n = 14/n = 19) with an initial learning effect due to the target were included for further statistical analysis. Within the subgroup incorrect responses upon NoGo stimuli increased during the deconditioning phase. In contrast, the same patients failed to show any change after receiving 200 mg of levodopa. During the Go version, no change of the overall error rate between conditioning and deconditioning was detectable over all groups. Learning behaviour in untreated PD patients and healthy controls was indistinguishable. In contrast, the same patients varied in their implicit learning after one-time intake of levodopa, when actions had to be inhibited. Hence, the single intake of levodopa appears to modulate implicit learning behaviour in de novo PD patients.

Entities:  

Keywords:  Dopamine; Go/NoGo paradigm; Implicit learninig; Non-motor smyptoms; Parkinson's disease; de novo diagnose

Mesh:

Substances:

Year:  2016        PMID: 27106907     DOI: 10.1007/s00702-016-1557-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  40 in total

1.  The dual-task SRT procedure: fine-tuning the timing.

Authors:  A T Hsiao; A S Reber
Journal:  Psychon Bull Rev       Date:  2001-06

2.  Learning and consolidation of visuo-motor adaptation in Parkinson's disease.

Authors:  Lucio Marinelli; Domenica Crupi; Alessandro Di Rocco; Marco Bove; David Eidelberg; Giovanni Abbruzzese; M Felice Ghilardi
Journal:  Parkinsonism Relat Disord       Date:  2008-04-18       Impact factor: 4.891

Review 3.  Implicit learning.

Authors:  C A Seger
Journal:  Psychol Bull       Date:  1994-03       Impact factor: 17.737

4.  Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteers.

Authors:  M A Mehta; R Swainson; A D Ogilvie; J Sahakian; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2001-09-11       Impact factor: 4.530

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

7.  Measuring fatigue in Parkinson's disease: a psychometric study of two brief generic fatigue questionnaires.

Authors:  Peter Hagell; Arja Höglund; Jan Reimer; Brita Eriksson; Ingmari Knutsson; Håkan Widner; David Cella
Journal:  J Pain Symptom Manage       Date:  2006-11       Impact factor: 3.612

8.  [Specific alterations in attention in the early stages of Parkinson's disease].

Authors:  E Alonso-Prieto; E M Esteban; C Trujillo-Matienzo; G E Lara-Fernández; T Roussó-Viota; A Cordero-Eiriz
Journal:  Rev Neurol       Date:  2003 Jun 1-15       Impact factor: 0.870

9.  Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function.

Authors:  Penny A Macdonald; Oury Monchi
Journal:  Parkinsons Dis       Date:  2011-03-06

10.  L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease.

Authors:  Roshan Cools; Simon J G Lewis; Luke Clark; Roger A Barker; Trevor W Robbins
Journal:  Neuropsychopharmacology       Date:  2006-07-12       Impact factor: 7.853

View more
  4 in total

1.  A single dose of L-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson's disease.

Authors:  Orsolya Györfi; Helga Nagy; Magdolna Bokor; Oguz Kelemen; Szabolcs Kéri
Journal:  J Neural Transm (Vienna)       Date:  2016-10-07       Impact factor: 3.575

2.  Dopaminergic Therapy Increases Go Timeouts in the Go/No-Go Task in Patients with Parkinson's Disease.

Authors:  Xue Q Yang; Brian Lauzon; Ken N Seergobin; Penny A MacDonald
Journal:  Front Hum Neurosci       Date:  2018-01-04       Impact factor: 3.169

3.  Diffusion Tensor Imaging of the Sciatic Nerve as a Surrogate Marker for Nerve Functionality of the Upper and Lower Limb in Patients With Diabetes and Prediabetes.

Authors:  Johann M E Jende; Zoltan Kender; Christoph Mooshage; Jan B Groener; Lucia Alvarez-Ramos; Jennifer Kollmer; Alexander Juerchott; Artur Hahn; Sabine Heiland; Peter Nawroth; Martin Bendszus; Stefan Kopf; Felix T Kurz
Journal:  Front Neurosci       Date:  2021-03-03       Impact factor: 4.677

4.  Continuous force measurements reveal no inhibitory control deficits in Parkinson's disease.

Authors:  Jade S Pickering; Iracema Leroi; Jennifer McBride; Ellen Poliakoff
Journal:  Exp Brain Res       Date:  2020-03-28       Impact factor: 1.972

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.